Experts’ consensus on intraoperative radiotherapy for pancreatic cancer

Yexiong Li, Qinfu Feng, Jing Jin, Susheng Shi, Zhihui Zhang, Xu Che, Jianwei Zhang, Yingtai Chen, Xiuhong Wu, Rufu Chen, Shengping Li, Jing Wang, Guang Li, Fei Li, Menghua Dai, Lei Zheng, Chengfeng Wang

Research output: Contribution to journalShort survey

Abstract

Pancreatic cancer (PC), one of the most lethal malignancies, accounts for 8%–10% of digestive system cancers, and the incidence is increasing. Surgery, chemotherapy, and radiotherapy have been the main treatment methods but are not very effective. However, only 20% of patients have the opportunity to undergo surgical operation. Approximately 30–40% of patients present with locally advanced, unresectable pancreatic cancer because of invasion of mesenteric vessels or adjacent organs. The first patient with unresectable pancreatic cancer was treated with Intraoperative radiotherapy (IORT) in 1959 [1]. Since then, new surgical and radiotherapeutic techniques have been developed, clinical trials have provided new evidence, and intriguing long-term effects have emerged from global metadatabases. IORT has the advantages of more accurate target, better local control rate, less complications, longer survival time and better life quality. During the past decade, IORT has been applied in some hospitals in the world, but there is little agreement on technical details and standards. A guidelines of IORT in pancreatic cancer is therefore necessary and timely. To develop standardized criteria for the application of IORT in pancreatic cancer, the experts from China to discuss treatment methods and arrive at a consensus on the indications, contraindications, and preferred techniques of IORT in pancreatic cancer. This detailed and agreed technical description of IORT may have implications on training, assessment, quality control, and future research.

Original languageEnglish (US)
Pages (from-to)1-7
Number of pages7
JournalCancer Letters
Volume449
DOIs
StatePublished - May 1 2019

Fingerprint

Pancreatic Neoplasms
Radiotherapy
Digestive System Neoplasms
Quality Control
China
Quality of Life
Clinical Trials
Guidelines
Drug Therapy
Survival
Incidence
Therapeutics
Neoplasms

Keywords

  • IORT
  • Pancreatic cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Li, Y., Feng, Q., Jin, J., Shi, S., Zhang, Z., Che, X., ... Wang, C. (2019). Experts’ consensus on intraoperative radiotherapy for pancreatic cancer. Cancer Letters, 449, 1-7. https://doi.org/10.1016/j.canlet.2019.01.038

Experts’ consensus on intraoperative radiotherapy for pancreatic cancer. / Li, Yexiong; Feng, Qinfu; Jin, Jing; Shi, Susheng; Zhang, Zhihui; Che, Xu; Zhang, Jianwei; Chen, Yingtai; Wu, Xiuhong; Chen, Rufu; Li, Shengping; Wang, Jing; Li, Guang; Li, Fei; Dai, Menghua; Zheng, Lei; Wang, Chengfeng.

In: Cancer Letters, Vol. 449, 01.05.2019, p. 1-7.

Research output: Contribution to journalShort survey

Li, Y, Feng, Q, Jin, J, Shi, S, Zhang, Z, Che, X, Zhang, J, Chen, Y, Wu, X, Chen, R, Li, S, Wang, J, Li, G, Li, F, Dai, M, Zheng, L & Wang, C 2019, 'Experts’ consensus on intraoperative radiotherapy for pancreatic cancer', Cancer Letters, vol. 449, pp. 1-7. https://doi.org/10.1016/j.canlet.2019.01.038
Li, Yexiong ; Feng, Qinfu ; Jin, Jing ; Shi, Susheng ; Zhang, Zhihui ; Che, Xu ; Zhang, Jianwei ; Chen, Yingtai ; Wu, Xiuhong ; Chen, Rufu ; Li, Shengping ; Wang, Jing ; Li, Guang ; Li, Fei ; Dai, Menghua ; Zheng, Lei ; Wang, Chengfeng. / Experts’ consensus on intraoperative radiotherapy for pancreatic cancer. In: Cancer Letters. 2019 ; Vol. 449. pp. 1-7.
@article{44a7bd238d7f46ddaba1c6878cc3c796,
title = "Experts’ consensus on intraoperative radiotherapy for pancreatic cancer",
abstract = "Pancreatic cancer (PC), one of the most lethal malignancies, accounts for 8{\%}–10{\%} of digestive system cancers, and the incidence is increasing. Surgery, chemotherapy, and radiotherapy have been the main treatment methods but are not very effective. However, only 20{\%} of patients have the opportunity to undergo surgical operation. Approximately 30–40{\%} of patients present with locally advanced, unresectable pancreatic cancer because of invasion of mesenteric vessels or adjacent organs. The first patient with unresectable pancreatic cancer was treated with Intraoperative radiotherapy (IORT) in 1959 [1]. Since then, new surgical and radiotherapeutic techniques have been developed, clinical trials have provided new evidence, and intriguing long-term effects have emerged from global metadatabases. IORT has the advantages of more accurate target, better local control rate, less complications, longer survival time and better life quality. During the past decade, IORT has been applied in some hospitals in the world, but there is little agreement on technical details and standards. A guidelines of IORT in pancreatic cancer is therefore necessary and timely. To develop standardized criteria for the application of IORT in pancreatic cancer, the experts from China to discuss treatment methods and arrive at a consensus on the indications, contraindications, and preferred techniques of IORT in pancreatic cancer. This detailed and agreed technical description of IORT may have implications on training, assessment, quality control, and future research.",
keywords = "IORT, Pancreatic cancer",
author = "Yexiong Li and Qinfu Feng and Jing Jin and Susheng Shi and Zhihui Zhang and Xu Che and Jianwei Zhang and Yingtai Chen and Xiuhong Wu and Rufu Chen and Shengping Li and Jing Wang and Guang Li and Fei Li and Menghua Dai and Lei Zheng and Chengfeng Wang",
year = "2019",
month = "5",
day = "1",
doi = "10.1016/j.canlet.2019.01.038",
language = "English (US)",
volume = "449",
pages = "1--7",
journal = "Cancer Letters",
issn = "0304-3835",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Experts’ consensus on intraoperative radiotherapy for pancreatic cancer

AU - Li, Yexiong

AU - Feng, Qinfu

AU - Jin, Jing

AU - Shi, Susheng

AU - Zhang, Zhihui

AU - Che, Xu

AU - Zhang, Jianwei

AU - Chen, Yingtai

AU - Wu, Xiuhong

AU - Chen, Rufu

AU - Li, Shengping

AU - Wang, Jing

AU - Li, Guang

AU - Li, Fei

AU - Dai, Menghua

AU - Zheng, Lei

AU - Wang, Chengfeng

PY - 2019/5/1

Y1 - 2019/5/1

N2 - Pancreatic cancer (PC), one of the most lethal malignancies, accounts for 8%–10% of digestive system cancers, and the incidence is increasing. Surgery, chemotherapy, and radiotherapy have been the main treatment methods but are not very effective. However, only 20% of patients have the opportunity to undergo surgical operation. Approximately 30–40% of patients present with locally advanced, unresectable pancreatic cancer because of invasion of mesenteric vessels or adjacent organs. The first patient with unresectable pancreatic cancer was treated with Intraoperative radiotherapy (IORT) in 1959 [1]. Since then, new surgical and radiotherapeutic techniques have been developed, clinical trials have provided new evidence, and intriguing long-term effects have emerged from global metadatabases. IORT has the advantages of more accurate target, better local control rate, less complications, longer survival time and better life quality. During the past decade, IORT has been applied in some hospitals in the world, but there is little agreement on technical details and standards. A guidelines of IORT in pancreatic cancer is therefore necessary and timely. To develop standardized criteria for the application of IORT in pancreatic cancer, the experts from China to discuss treatment methods and arrive at a consensus on the indications, contraindications, and preferred techniques of IORT in pancreatic cancer. This detailed and agreed technical description of IORT may have implications on training, assessment, quality control, and future research.

AB - Pancreatic cancer (PC), one of the most lethal malignancies, accounts for 8%–10% of digestive system cancers, and the incidence is increasing. Surgery, chemotherapy, and radiotherapy have been the main treatment methods but are not very effective. However, only 20% of patients have the opportunity to undergo surgical operation. Approximately 30–40% of patients present with locally advanced, unresectable pancreatic cancer because of invasion of mesenteric vessels or adjacent organs. The first patient with unresectable pancreatic cancer was treated with Intraoperative radiotherapy (IORT) in 1959 [1]. Since then, new surgical and radiotherapeutic techniques have been developed, clinical trials have provided new evidence, and intriguing long-term effects have emerged from global metadatabases. IORT has the advantages of more accurate target, better local control rate, less complications, longer survival time and better life quality. During the past decade, IORT has been applied in some hospitals in the world, but there is little agreement on technical details and standards. A guidelines of IORT in pancreatic cancer is therefore necessary and timely. To develop standardized criteria for the application of IORT in pancreatic cancer, the experts from China to discuss treatment methods and arrive at a consensus on the indications, contraindications, and preferred techniques of IORT in pancreatic cancer. This detailed and agreed technical description of IORT may have implications on training, assessment, quality control, and future research.

KW - IORT

KW - Pancreatic cancer

UR - http://www.scopus.com/inward/record.url?scp=85061646588&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061646588&partnerID=8YFLogxK

U2 - 10.1016/j.canlet.2019.01.038

DO - 10.1016/j.canlet.2019.01.038

M3 - Short survey

C2 - 30771429

AN - SCOPUS:85061646588

VL - 449

SP - 1

EP - 7

JO - Cancer Letters

JF - Cancer Letters

SN - 0304-3835

ER -